Target safety assessments and their role in de-risking drug discovery – Nav1.7 as an example


This poster, presented at the Gordon Research Conference in August 2017, concluded that:

Target safety assessments:

  • Provide expert assessment and interpretation of literature and available databases and are invaluable in identifying and avoiding target-related risks
  • Inform target selection and/or prioritisation early in discovery
  • Should contain the level of detail appropriate to the project stage
  • Should combine with emerging nonclinical and clinical data to build a picture that mitigates and manages risks at later stages in the project

Read more here:  Target Safety Assessments and Their Role in de-risking drug discovery: Nav1.7 as an example. Claire Sadler, Lauren Eades, Richard Knight, Michael Morton and Ruth Roberts.

By |2018-12-07T09:57:33+00:00August 20th, 2017|TSA Page, Target Safety Assessments, Publications|Comments Off on Target safety assessments and their role in de-risking drug discovery – Nav1.7 as an example

About the Author:

Professor Ruth A Roberts, PhD, ATS, FBTS, ERT, FRSB, FRCPath Director and Cofounder, ApconiX, UK and Chair and Director of Drug Discovery, University of Birmingham, UK Ruth is chair of drug discovery at Birmingham University, UK and Cofounder of ApconiX, an integrated toxicology and ion channel company that brings together a team of world-renowned nonclinical safety experts with over 400 years of drug discovery and development experience. Previously, Ruth was Global Head of Regulatory Safety at AstraZeneca and Director of Toxicology for Aventis. Ruth is an established science professional bringing rigorous expert thinking to toxicology, drug discovery and drug development. With >140 publications in peer reviewed journals, she is focused on reducing attrition attributable to safety and toxicity. A former president of the British Toxicology Society, former president of EUROTOX, former secretary to SOT and president elect of the Academy of Toxicological Sciences, Ruth was the recipient of the SOT Achievement award in 2002, the EUROTOX Bo Holmstedt Award in 2009 and the SOT Founders award in 2018 for outstanding leadership in toxicology.